Pipeline
Byondis is engineering precision-built ADCs to overcome cancer’s toughest challenges. Our proprietary pipeline combines novel payload platforms, advanced masking technology, and optimized linker strategies to tackle the cancers that current therapies cannot reach.
We create molecules that matter in the lives of patients – not just symptom-managing, but disease-modifying innovations. We call this “making hope real.”
Our pipeline reflects over 20 years of ADC expertise across research, lead identification, preclinical and clinical development, and manufacturing, all focused on enabling ADCs to fulfill their therapeutic potential.
Swipe
Pipeline: modular platforms for targeted solutions
We are rapidly advancing our lead proprietary program, BYON14156, to the clinic.
BYON4228
BYON4228 is a mAb from our next generation immuno-oncology (IO) program that targets and blocks the CD47-SIRPα axis, responsible for tumors’ ability to escape from recognition and destruction by the immune system.
Learn more
BYON4413
BYON4413 is an ADC directed against the molecular target CD123 (interleukin-3 receptor alpha chain), which is expressed on many hemato-oncological malignancies.
Learn moreOur Science
Byondis engineers differentiated ADCs to overcome cancer’s toughest challenges, combining novel payload platforms, advanced masking technology, and optimized linker strategies to deliver therapies with superior efficacy, safety, and duration of response.
Platforms
Our modular ADC platforms are generating potential first and best in class assets, including novel proprietary payloads, advanced masking technologies, and linker and drug conjugation strategies.